Update (June 30, 2026): Real-World CPMA Outcomes in a Shelter Setting — Length of Treatment, Cost, and Mortality

Bottom line.

• Hornback and Ferrell (2025, JSMCAH) report a 94-case retrospective study from the Oregon Humane Society shelter (2022-2024) comparing standard CPV-2 treatment with and without added CPMA.
• Adding CPMA to the shelter's established treatment protocol significantly reduced median length of treatment (3 days vs. 6.5 days) and average cost of treatment ($962 vs. $1,447).
• Mortality was numerically lower with CPMA (6% vs. 12%) but the difference was not statistically significant in this sample.
• This real-world shelter dataset complements the pivotal experimental-challenge trial, showing CPMA's practical impact on resource use in a high-volume, cost-constrained setting.
• This is a clinician-facing evidence summary - confirm current product labeling and shelter protocol applicability before use.

Study facts

• Setting: Limited-admission animal shelter (Oregon Humane Society, Portland, OR), retrospective observational design.
• Population: 94 dogs diagnosed with CPV-2 via IDEXX SNAP testing between 2022 and 2024; 43 treated with the shelter's standard protocol alone, 51 with standard protocol plus CPMA.
• Primary outcomes: Median length of treatment, average cost of treatment, mortality rate.
• Key result: Length of treatment and cost were both significantly reduced in the CPMA group; mortality reduction trended favorably but did not reach statistical significance.¹

Running a shelter or high-volume parvo caseload?

Get an instant cited answer for resource-allocation and triage decisions - no signup needed for your first question.

Try Voyage Clinical Desk

What the evidence shows

Study design

This retrospective observational study examined 94 cases of confirmed CPV-2 infection at a limited-admission shelter between 2022 and 2024. All dogs received the shelter's established parvovirus treatment protocol (supportive care including fluids, antiemetics, and antimicrobials); 51 of the 94 cases additionally received CPMA, while 43 did not. The authors compared median length of treatment, average cost of treatment, and mortality rate between the two groups.¹

Results

The CPMA group had a significantly shorter median length of treatment - 3 days (95% CI, 3.3-4.5) versus 6.5 days (95% CI, 5.5-7.4) in the non-CPMA group. Average cost of treatment was also significantly lower with CPMA: $962 (95% CI, $848-$1,140) versus $1,447 (95% CI, $1,243-$1,658) without it. Mortality was 6% in the CPMA group versus 12% in the standard-protocol-only group; this difference favored CPMA numerically but was not statistically significant given the sample size.¹ The authors concluded that adding CPMA to an established treatment program was associated with significant reductions in length and cost of treatment, though a mortality benefit could not be statistically confirmed in this cohort.

Context relative to the pivotal trial

These findings are consistent with, and extend, the experimental-challenge data from Larson et al. (2024), which found CPMA reduced morbidity (fever, vomiting, diarrhea duration, viral shedding) in addition to preventing mortality.² In a real-world shelter population with mixed strain exposure, comorbidities, and variable presentation severity (unlike the controlled, single-strain, age-matched experimental cohort), the morbidity-reduction effect appears to translate into the operationally meaningful outcomes of shorter hospital stay and lower cost per case - even though the smaller real-world sample size was underpowered to confirm a mortality difference.

How this fits clinical practice

For shelters and high-volume practices where kennel space, staff time, and per-case cost are binding constraints, this study provides a practical, real-world economic case for CPMA that complements the pivotal mortality-prevention data: a roughly 3.5-day reduction in median length of stay and approximately $485 lower average cost per case are clinically and operationally meaningful at scale, even without a statistically confirmed mortality benefit in this sample. Practices should weigh CPMA's acquisition cost against these downstream length-of-stay and resource savings, particularly in settings where bed turnover materially affects intake capacity. As with the pivotal trial, CPMA was used as an adjunct to - not a replacement for - the shelter's existing supportive-care protocol.

Always confirm current CPMA/Trutect product labeling and cost-effectiveness assumptions against your own practice's case mix and current pricing.

References

1. Hornback S, Ferrell E. 2025. Canine Parvovirus Monoclonal Antibody and Length of Treatment, Cost of Treatment, and Mortality in A Shelter Setting. J Shelter Med Community Anim Health 4(1). https://doi.org/10.56771/jsmcah.v4.159
2. Larson L, Miller L, Margiasso M, et al. 2024. Early Administration of Canine Parvovirus Monoclonal Antibody Prevented Mortality after Experimental Challenge. J Am Vet Med Assoc 262(4):506-512. https://avmajournals.avma.org/view/journals/javma/262/4/javma.23.09.0541.xml

Changelog

• 2026-06-30: First published.